Physician profile
Sanjay Jain
NPI 1114453842
$3,612.10
in general payments reported to CMS, 2019-2025
27 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.76 · 2021: $364 · 2022: $311 · 2023: $313 · 2024: $940 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $700.56 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $491.40 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $388.26 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $280.24 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $197.81 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Lilly USA, LLC | $193.80 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $169.11 | 2024-2025 | |
| Olympus America INC. | $150.71 | 2025 | Itind System |
| Janssen Pharmaceuticals, INC | $142.12 | 2024-2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $137.63 | 2021 | |
| Exact Sciences Corporation | $112.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $72.40 | 2024-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Antares Pharma, INC. | $72.16 | 2024-2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $68.90 | 2021-2023 | Seglentis |
| Amgen INC. | $65.94 | 2021-2024 | Krystexxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $57.74 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.34 | 2022 | |
| Glaxosmithkline, LLC. | $42.93 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.83 | 2024 | Ofev |
| Phadia US INC. | $33.70 | 2021-2022 | |
| Horizon Therapeutics Plc | $33.62 | 2021 | |
| Lucid Diagnostics INC. | $26.12 | 2022 | |
| Corcept Therapeutics | $22.31 | 2025 | Korlym |
| Eisai INC. | $19.75 | 2021 | |
| Lundbeck LLC | $19.38 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2025 | Camzyos |
| Halozyme INC | $13.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.